share_log

The Returns At Huaxia Eye Hospital GroupLtd (SZSE:301267) Aren't Growing

The Returns At Huaxia Eye Hospital GroupLtd (SZSE:301267) Aren't Growing

華夏眼科醫院集團有限公司的回報率不在增長
Simply Wall St ·  07/03 21:13

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. So, when we ran our eye over Huaxia Eye Hospital GroupLtd's (SZSE:301267) trend of ROCE, we liked what we saw.

如果你不確定下一個井噴股票的選股方向,那麼有幾個關鍵的趨勢是需要關注的。其中,我們需要看到兩個因素:首先,資本投入增長;其次,業務能夠不斷將收益再投入並獲得更高的回報。因此,當我們簡要了解中國科培教育集團(HKG:1890)的ROCE趨勢時,我們非常滿意所看到的。資產回報率:它是什麼?如果您不確定ROCE是什麼,它可以衡量公司能夠從其業務所僱用的資本產生多少稅前利潤。爲了計算V2X的這個指數,使用以下公式:0.054 = 1.24億美元÷(31億美元 - 8.53億美元)ROCE 趨勢可以告訴我們什麼?比起 Enphase Energy,有更好的資本回報率選擇。在過去的五年中,該公司增加了 1,306% 的資本,而該資本的回報率保持穩定在 9.9%。這樣差的回報率現在並不令人信服,而且隨着資本的增加,很明顯企業並沒有將資金投入到高回報的投資中。最終,這表明這是一家以逐漸提高投資回報率重新投資利潤的公司。 因此,當我們審查華夏眼科醫院集團有限公司(SZSE:301267)的ROCE趨勢時,我們喜歡我們所看到的。

Return On Capital Employed (ROCE): What Is It?

資本僱用回報率(ROCE)是什麼?

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. To calculate this metric for Huaxia Eye Hospital GroupLtd, this is the formula:

如果您以前沒有使用過ROCE,那麼它衡量公司從其業務所使用的資本中產生的“回報”(稅前利潤)。 要爲華夏眼科醫院集團有限公司計算這一指標,可使用以下公式:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

資產僱用回報率(ROCE)是指企業利潤,即企業稅前利潤除以企業投入的總資本(負債加股權)。如果ROCE高於企業財務成本的承受能力,那麼企業就會創造出更多的價值。

0.13 = CN¥875m ÷ (CN¥7.5b - CN¥975m) (Based on the trailing twelve months to March 2024).

0.13 = CN¥87500萬 ÷ (CN¥75億 - CN¥975m)在Elevance Health上,我們已經注意到的趨勢是相當令人放心的。數據顯示,過去五年資產回報率大幅提高至15%。投資所用資產的規模也增加了30%。這表明有很多機會進行內部資本投資,並以更高的速度不斷增長,這種組合在多倍增長方面很常見。.

Thus, Huaxia Eye Hospital GroupLtd has an ROCE of 13%. In absolute terms, that's a satisfactory return, but compared to the Healthcare industry average of 9.5% it's much better.

因此,華夏眼科醫院集團有限公司的ROCE爲13%。從絕對數值來看,這是一個令人滿意的回報,但與醫療保健行業的平均9.5%相比,則更高。

roce
SZSE:301267 Return on Capital Employed July 4th 2024
SZSE:301267 資本運作回報率 2024年7月4日

Above you can see how the current ROCE for Huaxia Eye Hospital GroupLtd compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for Huaxia Eye Hospital GroupLtd .

您可以看到華夏眼科醫院集團有限公司目前的資本回報率與其以往的回報率相比如何,但從過去,我們能了解的信息僅有限。如果您感興趣,可以在我們爲華夏眼科醫院集團有限公司提供的免費分析師報告中查看分析師的預測。

The Trend Of ROCE

當尋找下一個倍增器時,如果您不確定從哪裏開始,請關注幾個關鍵趨勢。首先,我們希望看到一個經過驗證的資本使用率。如果您看到這一點,通常意味着這是一家擁有出色業務模式和大量盈利再投資機會的公司。然而,調查蒙托克可再生能源公司(NASDAQ:MNTK)後,我們認爲它的現行趨勢不符合倍增器的模式。

While the returns on capital are good, they haven't moved much. The company has consistently earned 13% for the last five years, and the capital employed within the business has risen 365% in that time. Since 13% is a moderate ROCE though, it's good to see a business can continue to reinvest at these decent rates of return. Over long periods of time, returns like these might not be too exciting, but with consistency they can pay off in terms of share price returns.

儘管資本回報率表現良好,但其變動不大。過去5年中,該公司的回報率一直保持在13%,業務所使用的資本在同一時期內增長了365%。 儘管13%是適度的ROCE,但看到企業能夠以這些合理的回報率繼續重新投資是一件好事。 長時間來看,這樣的回報可能不太令人興奮,但如果保持穩定,這些回報可以帶來股票回報方面的收益。

One more thing to note, even though ROCE has remained relatively flat over the last five years, the reduction in current liabilities to 13% of total assets, is good to see from a business owner's perspective. This can eliminate some of the risks inherent in the operations because the business has less outstanding obligations to their suppliers and or short-term creditors than they did previously.

值得注意的另一件事是,儘管過去5年中ROCE相對穩定,但當前負債的降低使得企業所有者有所眼福。從商業主的角度來看,這可以消除一些運營中固有的風險,因爲企業所欠供應商或短期債權人的未償餘額相對以往更少。

What We Can Learn From Huaxia Eye Hospital GroupLtd's ROCE

我們能從華夏眼科醫院集團有限公司的ROCE中學到的東西

The main thing to remember is that Huaxia Eye Hospital GroupLtd has proven its ability to continually reinvest at respectable rates of return. However, despite the favorable fundamentals, the stock has fallen 47% over the last year, so there might be an opportunity here for astute investors. For that reason, savvy investors might want to look further into this company in case it's a prime investment.

要記住的主要事情是,華夏眼科醫院集團有限公司已證明其能夠以可觀的回報率不斷重新投資。 然而,儘管基本面良好,該股票在過去一年中下跌了47%,因此聰明的投資者可能會在這裏尋找機會。 因此,明智的投資者可能希望進一步研究這家公司,以防其成爲一個開空的投資。

While Huaxia Eye Hospital GroupLtd doesn't shine too bright in this respect, it's still worth seeing if the company is trading at attractive prices. You can find that out with our FREE intrinsic value estimation for 301267 on our platform.

雖然華夏眼科醫院集團有限公司在這方面並不太出色,但看看該公司是否以有吸引力的價格交易仍然值得。您可以在我們的平台上使用免費內在價值估算工具來了解情況。

While Huaxia Eye Hospital GroupLtd isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

儘管華夏眼科醫院集團有限公司的回報率不是最高的,但請查看此免費公司清單,這些公司具有實力平衡表和盈利能力。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論